trizzle Posted - 2 days ago

$GMAB 💩 sandwich here. The don’t want to help longs

trizzle Posted - 3 days ago

$GMAB lets go GMAB leaders. This is not how you gain investors.

G101SPM Posted - 5 days ago

$GMAB $29.25 bid. DAC $29.52 (4.16.24). EXIT $40.00. EVENT: Genmab Announces Presentation Of Multiple Abstracts On Epcoritamab At 2024 European Hematology Association Congress On June 13-16.

briefingcom Posted - 5 days ago

$GMAB: Genmab to present new and updated results from multiple clinical trials evaluating epcoritamab across various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

DonCorleone77 Posted - 5 days ago

$GMAB Genmab to present new, updated results from abstracts evaluating epcoritamab Genmab announced that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2024 European Hematology Association Congress, being held in Madrid, Spain and virtually, June 13-16, 2024. Presentations will include data from clinical trials evaluating the safety and efficacy of epcoritamab as a monotherapy and in combination with standard-of-care or other novel therapies across multiple patient populations. Three oral presentations will highlight data from the pivotal and cycle 1 dose optimization cohorts of EPCORE NHL-1 evaluating epcoritamab in patients with relapsed/refractory follicular lymphoma, from EPCORE NHL-5 evaluating epcoritamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone as a potential first-line treatment regimen for patients with diffuse large B-cell lymphoma, and from EPCORE CLL-1 evaluating epcoritamab in patients with Richter's transformation. "Building on the recent global regulatory approvals and pending regulatory decisions for epcoritamab, we look forward to presenting new data at EHA 2024 that highlight the key progress that has been made developing epcoritamab as a potential core therapy across a variety of B-cell malignancies," said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. "Together with AbbVie, we are committed to advancing and evolving the robust development program evaluating epcoritamab, as a monotherapy and in combination, across B-cell malignancies and settings."

Stock_Titan Posted - 5 days ago

$GMAB Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress https://www.stocktitan.net/news/GMAB/genmab-to-present-new-and-updated-results-from-multiple-clinical-ojvxugbudlv3.html

DonCorleone77 Posted - 6 days ago

$NVO $RHHBY $GMAB Novo Nordisk mim8 data near Jefferies' 'best' case scenario Jefferies says positive headline Phase 3 data for Novo Nordisk's (NVO) mim8 in haemophilia A "may near our 'best' case scenario," with convenient once-monthly dosing seeming similarly effective to once-weekly and efficacy data that may challenge Roche's (RHHBY) incumbent Hemlibra. Based on the press release, the firm "could justify modest" Novo stock upside, Genmab (GMAB) shares being up 2%-4% and Roche shares being down 2%-3%, the analyst tells investors. Jefferies has an Underperform rating on Novo shares and Hold ratings on both Genmab and Roche.

Source65 Posted - 1 week ago

$GMAB This stock is stuck near its 52 week low , even with good earnings and a stock buyback . No follow through by the buyers in the market . If I can’t move with favorable tailwinds that’s a problem

trizzle Posted - 1 week ago

$GMAB one year chart looks pathetic. Leadership is not supporting longs at all.

trizzle Posted - 1 week ago

$GMAB they just posted great numbers. Where are the buyers that also invest in $JNJ or $BMY or $GSK

DonCorleone77 Posted - 2 weeks ago

$GMAB Citi opens 'positive catalyst watch' on Genmab into data Citi opened a "90-day positive catalyst watch" on shares of Genmab while keeping a Sell rating on the shares. The company's Q1 sales beat consensus and the stock's risk/reward into ASCO is appealing, the analyst tells investors in a research note. The firm says the earnings call commentary that GEN1046 data at ASCO will include overall survival as well as progression free survival data makes for an interesting risk/reward.

Hawaiianinvesta Posted - 2 weeks ago

$GMAB stellar results, anything under 3 is an absolute steal

DonCorleone77 Posted - 2 weeks ago

$GMAB Genmab maintaining 2024 financial guidance Genmab is maintaining its 2024 financial guidance published on February 14, the company noted. Genmab said: "Following the announcement of the proposed acquisition of ProfoundBio, Genmab's operating expenses before expenses incurred by it in connection with the proposed transaction are now anticipated to be at or moderately above the upper end of the previously disclosed guidance range of DKK 12.4 -13.4B. The anticipated increase reflects the incremental R&D investment to support the advancement of ProfoundBio's clinical programs, primarily Rina-S. Genmab's revenue guidance is unchanged and expected to be in the previously disclosed guidance range of DKK 18.7 - 20.5B. We expect to update our guidance no later than in connection with our second quarter 2024 earnings."

DonCorleone77 Posted - 2 weeks ago

$GMAB $JNJ $NVS $ABBV $PFE Genmab reports Q1 revenue increased 46% vs. last year Revenue was DKK 4.143B for the first three months of 2024. compared to DKK 2.834B for the first three months of 2023. The increase of DKK 1.309B, or 46%, was primarily driven by higher Darzalex and Kesimpta royalties achieved under collaborations with Janssen (JNJ) and Novartis Pharma (NVS), respectively, EPKINLY net product sales, and a milestone achieved under the company's collaboration with AbbVie (ABBV), Genmab (GMAB) stated. Operating profit was DKK 801M in the first three months of 2024, compared to DKK 417M in the first three months of 2023. "The acceptance for Priority Review by the U.S. FDA of the sBLAs for EPKINLY and Tivdak that we received in the first quarter are important events that support our commitment to continue to deliver innovative treatment options that have the potential to profoundly impact the lives of patients. These regulatory acceptances for priority review also reflect our dedication to working with our partners, AbbVie Inc. and Pfizer Inc. to expand the labels for EPKINLY and Tivdak, respectively, in order to maximize the potential of both medicines and bring them to as many patients in need of alternative therapeutic options as possible," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

trizzle Posted - 04/30/24

$GMAB do we hit $40 this quarter? Good earnings may help

Source65 Posted - 04/29/24

$GMAB This baby bout to fly ..great announcement today and earnings on deck this week

DonCorleone77 Posted - 04/29/24

$GMAB $PFE Genmab-Pfizer gain full FDA approval for TIVDAK in Metastatic Cervical Cancer Pfizer (PFE) and Genmab A/S (GMAB) "announced the FDA approves the supplemental Biologics License Application granting full approval for TIVDAK, or tisotumab vedotin-tftv, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The approval is based on results from the global, randomized, Phase 3 innovaTV 301 clinical trial, which met its primary endpoint, demonstrating overall survival benefit in adult patients with previously treated recurrent or metastatic cervical cancer treated with TIVDAK compared to chemotherapy. Secondary endpoints of progression-free survival (PFS) and confirmed objective response rate were also met. In October 2023, results from the innovaTV 301 study were presented during the Presidential session at the European Society of Medical Oncology Congress. The innovaTV 301 study demonstrated a 30% reduction in the risk of death compared to chemotherapy. Median OS for patients treated with TIVDAK was 11.5 months versus chemotherapy 9.5 months."

Stock_Titan Posted - 04/29/24

$GMAB $PFE TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer https://www.stocktitan.net/news/GMAB/tivdak-r-tisotumab-vedotin-tftv-receives-u-s-fda-approval-to-treat-byw43lzntzn0.html

Stock_Titan Posted - 04/29/24

$PFE $GMAB FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer https://www.stocktitan.net/news/PFE/fda-grants-full-approval-for-tivdak-r-to-treat-recurrent-or-uj9srfbbgi3n.html

Gutsman Posted - 04/25/24

$GMAB Earnings on the 2nd, on the FDA calendar the week after. Looks like it is time to start buying shares

G101SPM Posted - 04/22/24

$GMAB $28.70 bid. DAC (dollar average cost) $29.52 (4.17.24). EXIT $40.00. UPDATE: On March 15, 2024, Genmab(GMAB) announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. ^ Transactions April 15, 2024 to April 19, 2024: Total 32,701 1,984.26 64,887,132.57 Total 39,367 281,116,033.75 Accumulated 408,701 836,159,512.12 Following these transactions, Genmab(GMAB) holds 1,269,043 shares as treasury shares, corresponding to 1.92% of the total share capital and voting rights.

G101SPM Posted - 1 month ago

$GMAB $29.52 bid. BUY/NEW LONG POSITION carries SPM 87.86 tag to $40 EXIT.

CDMO Posted - 1 month ago

$GMAB 23% increased darzalex sales YoY for JnJ, nice increase in royalties for genmab

trizzle Posted - 1 month ago

$GMAB come on. Great profits, growing pipeline, boring investment. At least pay a dividend if going to be this pathetic. Should be 40-50 this year.

CDMO Posted - 1 month ago

$GMAB tempted to add here once again

HoHoHoHum Posted - 1 month ago

$GMAB been looking at this after yesterdays acquisition news. company has great cash flow excellent balance sheet and a solid promising pipeline. has the potential to hit 100 in 3-4 years.

tradethehalt Posted - 1 month ago

$GMAB Genmab Expands Oncology Portfolio with $1.8 Billion ProfoundBio Acquisition. https://www.reuters.com/markets/deals/denmarks-genmab-acquire-profoundbio-18-billion-2024-04-03/

Stock_Titan Posted - 1 month ago

$GMAB Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio https://www.stocktitan.net/news/GMAB/genmab-to-broaden-and-strengthen-oncology-portfolio-with-acquisition-oxr2p2kn7l8u.html

CDMO Posted - 1 month ago

$GMAB just an article about gmab https://www.fiercepharma.com/pharma/genmab-nabs-lease-us-expansion-it-looks-boost-marketing-its-abbvie-partnered-lymphoma-med

Digital_Waffle_Pirate Posted - 03/30/24

$GMAB interesting